Loading...
Loading...
NERVGEN PHARMA CORP.
NERVGEN PHARMA CORP.. Spoken Alpha tracks NGEN's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks NGEN's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 90% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NGEN.
curl https://api.spokenalpha.com/v1/companies/NGEN| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.13 | $1.61 | +32.5% | -6.1% | -7.3% |
| Q4 FY2026 | $2.06 | $1.60 | +29.0% | -1.3% | -3.0% |
| Q3 FY2026 | $2.49 | $1.84 | +35.2% | -8.5% | -9.7% |
| Q2 FY2026 | $2.44 | $1.83 | +33.4% | -8.5% | -7.5% |
| Q1 FY2025 | $2.52 | $1.92 | +31.3% | -6.9% | -8.1% |
| Q4 FY2025 | $2.64 | $1.83 | +44.2% | +0.8% | +2.2% |
| Q3 FY2025 | $2.39 | $1.68 | +42.1% | -0.5% | -2.0% |
| Q2 FY2025 | $2.45 | $1.75 | +39.8% | -5.0% | -3.3% |
| Q1 FY2024 | $2.60 | $1.91 | +36.2% | -7.4% | -5.1% |
| Q4 FY2024 | $2.35 | $1.76 | +33.7% | -1.9% | -1.3% |